Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Epilepsia Open
2016 Sep 19;13-4:145-151. doi: 10.1002/epi4.12015.
Show Gene links
Show Anatomy links
Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin.
Morano A
,
Cifelli P
,
Nencini P
,
Antonilli L
,
Fattouch J
,
Ruffolo G
,
Roseti C
,
Aronica E
,
Limatola C
,
Di Bonaventura C
,
Palma E
,
Giallonardo AT
.
???displayArticle.abstract???
Cannabidivarin (CBDV) and cannabidiol (CBD) have recently emerged among cannabinoids for their potential antiepileptic properties, as shown in several animal models. We report the case of a patient affected by symptomatic partial epilepsy who used cannabis as self-medication after the failure of countless pharmacological/surgical treatments. Clinical and video electroencephalogram (EEG) evaluations were periodically performed, and the serum levels of CBDV, CBD, and Δ9-tetrahydrocannabinol were repeatedly measured. After cannabis administration, a dramatic clinical improvement, in terms of both decrease in seizure frequency and recovery of cognitive functions, was observed, which might parallel high CBDV plasma concentrations. To widen the spectrum of CBDV possible mechanisms of action, electrophysiological methods were applied to investigate whether it could exert some effects on γ-aminobutyric acid (GABA)A receptors. Our experiments showed that, in human hippocampal tissues of four patients affected by drug-resistant temporal lobe epilepsy (TLE) transplanted in Xenopus oocytes, there is decrease of current rundown (i.e., reduction of use-dependent GABAA current) after prolonged exposure to CBDV. This result has been confirmed using a single case of Rasmussen encephalitis (RE). Our patient's electroclinical improvement supports the hypothesis that cannabis could actually represent an effective, well-tolerated antiepileptic drug. Moreover, the experimental data suggest that CBDV may greatly contribute to cannabis anticonvulsant effect through its possible GABAergic action.
Figure 1. (A) EEG recording performed before the introduction of cannabis: the tracing shows a subcontinuous paroxysmal epileptiform activity characterized by discharges of spikes in the left hemisphere with rapid contralateral transmission, followed by a brief voltage attenuation on the left frontocentral and anterior temporal regions, and then by a pseudoperiodic slow spikeâandâwave activity propagating over the midposterior temporal areas. The clinical correlate consisted of a seizure characterized by intense right perioral myoclonus (*), followed by ipsilateral tonic deviation of the mouth (â), dystonic posturing of the right limbs (â¦), and partial consciousness impairment ().The neurological examination showed severe ideomotor slowing and an evident worsening of the preexistent aphasia, with increased difficulty in verbal comprehension and word reaching. (B) EEG recording performed 1 year after the introduction of cannabis: the tracing shows diffuse discharges of spikes, clinically associated with isolated perioral myoclonus (*), and focal thetaâdelta activity intermingled with spikes and spikeâandâwaves located on the frontal and anterior and middle temporal regions. An improvement in cognitive and, more specifically, language functions was observed. (C) MRI scan (FLAIR and IR sequences). On the left: MRI scan before surgery, showing the presence of a lesion involving the left insula with concomitant slight hyperintensity and bulging of the mesial temporal area and atrophy of the head of the ipsilateral caudate nucleus. On the right: MRI scan after left temporal lobectomy, showing diffuse white matter alterations and leftlateralventricle dilatation.
Figure 2. (A) Cannabinoids serum levels and electroclinical correlations. B: baseline, defined as the coexistence of subcontinuous motor seizures (right perioral myoclonus, ipsilateral tonic deviation of the mouth, dystonic posturing of the right limbs, and partial consciousness impairment) and severe ideomotor slowing with mixed aphasia; PI: partial improvement, defined as the coexistence of perioral myoclonia, subclinical ictal discharges, and motor aphasia; I: improvement, defined as the persistence of isolated perioral myoclonic jerks and the improvement of language fluency. Plasma concentrations of Î9âtetrahydrocannabinol (THC), cannabidiol (CBD), and cannabidivarin (CBDV) were quantified by liquid chromatography tandem mass spectrometry (LCâMS/MS) according to Ferreiròs et al. with slight modifications. After solid phase extraction (SPE), chromatography was performed on KInetex C18 column (50 à 2.1 mm, 2.6 particle size) with a gradient of 0.01% formic acid in water and 0.01% formic acid in methanol. THC and CBDV were monitored using positive mode electrospray ionization and multiple reaction monitoring (MRM). The transitions were m/z 315 â 193 and 287.2 â 165.2 for THC and CBDV, respectively. The limit of quantification (LOQ) was 0.5 ng/ml for both analyses. (B) Normalized timeâcourse of the averaged (mean ± SEM) GABA current rundown in oocytes transplanted with hippocampal membranes in control condition (filled symbol) and after 50 nm
CBDV application (empty symbol). Data refer to 30 oocytes, 4 patients. In all experiments the holding potential was â60 mV. Current amplitude normalized to the first response of rundown protocol. Inset: Representative GABA current traces in one transplanted oocyte showing the first and sixth response to GABA 500 μm (black bars) before and after 50 nm
CBDV application as indicated. Data refer to 4 TLE patients (4 males, mean age 32.7 ± 9.5 years; mean epilepsy onset 12.7 ± 1 years). All patients had mainly complex partial seizures resistant to maximal doses of different antiepileptic drugs and had hippocampal sclerosis (HS) with neuronal loss within all hippocampal subfields, including CA1 and CA4 (HS, ILAE type 1). For the clinical part of the study, informed consent was obtained. For the experiments, TLE tissues with HS were provided by Amsterdam University (AMC) and used in accordance with the Declaration of Helsinki.
Devinsky,
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
2014, Pubmed
Devinsky,
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
2014,
Pubmed
Eusebi,
Microtransplantation of ligand-gated receptor-channels from fresh or frozen nervous tissue into Xenopus oocytes: a potent tool for expanding functional information.
2009,
Pubmed
,
Xenbase
Friedman,
Cannabinoids in the Treatment of Epilepsy.
2015,
Pubmed
Golovko,
Control of Inhibition by the Direct Action of Cannabinoids on GABAA Receptors.
2015,
Pubmed
Hill,
Cannabidivarin is anticonvulsant in mouse and rat.
2012,
Pubmed
Hill,
Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism.
2013,
Pubmed
Iannotti,
Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability.
2014,
Pubmed
Koppel,
Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.
2014,
Pubmed
Maa,
The case for medical marijuana in epilepsy.
2014,
Pubmed
Mathern,
Fewer specialists support using medical marijuana and CBD in treating epilepsy patients compared with other medical professionals and patients: result of Epilepsia's survey.
2015,
Pubmed
Palma,
The antiepileptic drug levetiracetam stabilizes the human epileptic GABAA receptors upon repetitive activation.
2007,
Pubmed
,
Xenbase
Palma,
Phosphatase inhibitors remove the run-down of gamma-aminobutyric acid type A receptors in the human epileptic brain.
2004,
Pubmed
,
Xenbase
Patsalos,
Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs.
2003,
Pubmed
Roseti,
Fractalkine/CX3CL1 modulates GABAA currents in human temporal lobe epilepsy.
2013,
Pubmed
,
Xenbase